Sir,

Neurothekeomas were described in 1980 as benign cutaneous tumors of nerve sheath differentiation. Subsequent authors suggested neurothekeomas represented variants of dermal nerve sheath myxomas.\[[@ref1]\] However, subtle morphologic differences, divergent immunohistochemical staining in human tissue, and ultrastructural studies led many authors to question the relationship between neurothekeomas and nerve sheath myxomas.

A 25-year-old female had 0.7 cm sized single subcutaneous nodule with tenderness on her left thumb \[[Figure 1](#F1){ref-type="fig"}\]. After excision, specimen showed sharply marginated nodule in the dermis with the multi-lobular structures and amorphous myxoid matrix \[[Figure 2a](#F2){ref-type="fig"}\]. Within the myxoid matrix, there were scattered collections of epithelioid Schwann cells in corded, nested, ring-like morphology and syncytial-like aggregation \[Figure [2b](#F2){ref-type="fig"}--[d](#F2){ref-type="fig"}\]. These cells were immunoreactive for S-100 protein, neuron specific enolase (NSE), vimentin, NKI/C3, and non-reactive for glial fibrillary acidic protein (GFAP), smooth muscle actin (SMA), CD10, CD68 \[[Figure 3](#F3){ref-type="fig"}\].

![A solitary 7 mm sized, subcutaneous mass on left thumb](IJD-59-99-g001){#F1}

![(a) Sharply marginated multiple lobules with abundunt mxyoid matrix in dermis (H and E, ×40). (b) Corded aggregation of epihelioid Schwann cells in tumor (H and E, ×200). (c) A variable number of Schwann cells with a ring-like appearance, (H and E, ×200). (d) Syncytial-like aggregation of Schwann cells (H and E, ×200)](IJD-59-99-g002){#F2}

![Immunohistochemical staining results](IJD-59-99-g003){#F3}

In previous studies, they reported that nerve sheath myxomas involved finger, knee or pretibial region commonly in 3^rd^ and 4^th^ decades of patients. The male-to-female ratio was almost 1:1. On the other hand, neurothekeomas arose most often on the upper limb or head and neck in 2^nd^ and 3^rd^ decades of patents. There was a 1.8:1 female predominance. Tumors of both diseases were similarly described as painless subepidermal nodule.\[[@ref2][@ref3]\]

To date, there is ambiguous disease definition between nerve sheath myxomas and neurothekeomas. Recent studies argued that these two diseases are distinct and suggested S-100 protein staining as the crucial reason, not histological findings.\[[@ref2][@ref4]\] This was also consistent with our case results. Other immunoreactive staining for nerve sheath myxomas are GFAP, CD57, NSE. Neurothekeomas showed positive staining results for NKI/C3, NSE, and SMA. However, all other staining couldn't show 100% result consistency, except S-100 protein. Recently, study using the microarray-based gene expression profile showed that S-100B gene was the most significantly differentially expressed gene between the nerve sheath myxomas and the neurothekeomas.\[[@ref4]\] This molecular finding correlates with recent immunohistochemical observations and provides the molecular support for recent work reporting negative S100 protein staining by immunohistochemistry in neurothekeomas of all subtypes.\[[@ref4]\]

There was one report about soft-tissue tumor of hand in a 5 month old infant.\[[@ref5]\] Spindle cells in specimen showed positive staining for S-100, and alcian blue for mucoid stroma. And they diagnosed this as myxoid neurothekeoma. However, according to recent reported studies above mentioned, we suppose attentively that it is better to be diagnosed as nerve sheath myxoma than the neurothekeoma.

Hence, we support that nerve sheath myxoma is a distinct disease of nerve sheath derivation distinguished with the neurothekeoma and S-100 protein staining would be the most powerful criteria to discriminate these diseases.
